CCR

38 Items

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. CCR antagonist

    Maraviroc is an antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection.
  2. CCR5 antagonist

    Vicriviroc Malate is a second generation orally active CCR5 antagonist, which is also a potent inhibitor of HIV-1 entry into target cells, with a mean IC50 =0.46 nM and IC50 =1~10 nM to HIV isolates (n=52).
  3. HCCR2 antagonist

    INCB 3284 dimesylate is a potent, selective hCCR2 antagonist that exhibits potenct antagonism against monocyte chemoattractant molecule binding to hCCR2 and chemotaxis activity.
  4. CCR2 antagonist

    MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models.
  5. CCR2 Antagonist

    INCB8761(PF-4136309) is a potent, selective, and orally bioavailable CCR2 antagonist.
  6. CCR2 antagonist

    INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.
  7. CCR4 antagonist

    GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96??0.11.
  8. CCR 2 antagonist

    Teijin compound 1 is a specific CCR 2 antagonist with IC50s of 24 and 180 nM in chemotaxis and binding assay, respectively.
  9. CCR5 entry inhibitor

    Aplaviroc is a CCR5 entry inhibitor developed for the treatment of HIV infection.
  10. CCR2/CCR5 inhibitor

    Cenicriviroc is an experimental drug candidate for the treatment of HIV infection.Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell.
  11. CCR5 antagonist

    TAK-779 is a novel, potent and selective small-molecule antagonists of CCR5 with the IC50 value of 1.4nM in binding assay.
  12. CCR1 antagonist

    BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1), exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
  13. CCR2 antagonist

    PF-4136309 is a potent, selective, and orally bioavailable CCR2 antagonist, with IC50s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.
  14. CCR2 antagonist.

    RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 uM for inhibition of human recombinant CCR2b and CCR1 receptors respectively).
  15. CCR5 antagonist

    Vicriviroc maleate is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1.
  16. CCR1 agonist

    NSC5844 is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.
  17. CCR8 agonist

    ZK-756326 is a potent, selective and non-peptide CCR8 chemokine receptor agonist. ZK 756326 inhibited the binding of the CCR8 ligand I-309 (CCL1), with an IC(50) value of 1.8 μM.
  18. CCR2/5 receptors inhibitor

    Cenicriviroc, also known as TAK-652 and TBR-652, is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. CAS: 199673-74-0(LY 334370 hydrochloride); 182563-08-2 (LY 334370 Free Base)
  19. CCR2/CCR5 antagonist

    BMS-813160 is a potent and selective CCR2/CCR5 antagonist with potential immunomodulating and antineoplastic activities.
  20. CCR4 antagonist

    CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues.
  21. CCR8 agonist

    LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM.
  22. CCR2 /CCR5 dual antagonist

    PF-04634817 is an orally administered CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema.
  23. Human CCR1 antagonist

    BI-639667 is a potent and selective antagonist of human CCR1.
  24. CCR8 inhibitor

    ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations.
  25. CCR8 antagonist

    AZ084 is a potent, selective, allosteric and oral active CCR8 antagonist, with a Ki of 0.9 nM. Has potential to treat asthma.
  26. CCR3 antagonist

    SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.
  27. CCR2 antagonist

    CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM.
  28. CCR3 antagonist

    GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.
  29. CX3CR1 modulator

    E6130 is an orally available and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.
  30. CCR5 antagonist

    CCR5 antagonist 1 is a CCR5 antagonist which can inhibit HIV replication extracted from WO 2004054974 A2.
  31. CCR2 antagonist

    CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist.
  32. CCR5 antagonist

    TAK-220 is a selective and orally bioavailable CCR5 antagonist.
  33. CCR2 antagonist

    CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine receptor type 2 (CCR2) with an IC50 of 103 nM.
  34. CCR2 antagonist

    RS102895 hydrochloride is a potent CCR2 antagonist, with an IC50 of 360 nM, and shows no effect on CCR1.
  35. CCR9 antagonist

    Vercirnon (GSK-1605786) is an orally bioavailable, selective, and potent antagonist of CCR9, with an IC50 of 10 nM, used in the research of inflammatory bowel diseases.
  36. non-peptide CCR1 antagonist

    BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist with Ki of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
  37. CCR8 inhibitor

    R243 is an inhibitor of CCR8 signaling and chemotaxis.
  38. CCR5 antagonist

    Nifeviroc is a CCR5 antagonist potentially for treatment of inflammatory responses to HIV type-1 infection

38 Items

per page
Set Descending Direction